GVAX is a whole‐cell vaccine in which pancreatic cancer cells are engineered to express the proinflammatory cytokine granulocyte monocyte‐colony stimulating factor (GM‐CSF) to further stimulate APC antigen uptake and T‐cell priming.25 A phase I study evaluated the safety and efficacy of GVAX as an adjuvant therapy given in series with chemoradiation therapy in patients with resected pancreatic cancer. The gene discussed is CSF2; the disease is pancreatic neoplasm.